According to Nissen, other potentially safer alternatives to Avandia -- such as its class equivalent Actos -- suggest Avandia is not a necessary medication for a majority of diabetes patients. There are no unique benefits to Avandia, he said.
"If [Avandia] was the only drug in the class, [we] could have an argument to keep it around," said Nissen.
Nissen said a 2007 presentation to the FDA advisory board by Graham estimated that more than 200,000 patients died from taking Avandia since possible cardiovascular effects of the drug were first reported.
"I think the conclusion is pretty clear," said Nissen. "Now let's get on with it. Get this drug off the market."
Dr. Steve Nissen is a paid consultant for pharmaceutical companies, including GlaxoSmithKline, and Takeda Pharmaceuticals. Nissen said he donates all compensation to various organizations. Dr. Domenic Sica is a consultant and investigator for Takeda in the area of hypertension.